Clinically significant cytomegalovirus infection (csCMVi) after matched related donor allogeneic HSCT using post-transplant cyclophosphamide: A systematic review and meta-analysis. (ASH 2025) - Nov 4, 2025 - Abstract #abs25-4252; 5970; Pres time: Dec 8, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Background :Post-transplant cyclophosphamide (PTCy) is increasingly used as graft-versus-host disease (GVHD)prophylaxis in matched related donor (MRD) allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite the use of PTCy in MRD allo-HSCT, clinically significant CMV infection remains a frequent andclinically relevant complication, with pooled incidence approaching 30%. The marked heterogeneityunderscores the need for consistent antiviral prophylaxis and stratified CMV risk assessment.Theconsistent absence of anti-CMV prophylaxis such as Letermovir underscores the need for standardizedprevention protocols. Notably, data on CMV incidence in patients receiving prophylaxis are lacking,warranting further studies."
Post-transplantation • Retrospective data • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Transplantation
|
|
Rishi Bothara1; Varshini Thiruvadi1; Manasa Kandula1
|